Oxbow Advisors’s AstraZeneca AZN Stock Holding History

Oxbow Advisors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.47M	Sell	39,379 -1,173	-3%	-$221K	0.61%	36
2026 Q1	$8M	Buy	40,552 +1,408	+4%	+$271K	0.68%	38
2025 Q4	$7.2M	Buy	39,144 +347	+0.9%	+$60.9K	0.63%	40
2025 Q3	$5.95M	Buy	38,797 +19,021	+96%	+$2.88M	0.55%	48
2025 Q2	$2.76M	Buy	19,776 +722	+4%	+$101K	0.3%	82
2025 Q1	$2.8M	Buy	19,054 +382	+2%	+$55.3K	0.3%	73
2024 Q4	$2.45M	Buy	18,672 +17,193	+1,162%	+$2.41M	0.29%	82
2024 Q3	$230K	Buy	+1,479	New	+$239K	0.02%	187

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Oxbow Advisors's AZN Position: Q2 2026 in Review

Oxbow Advisors reduced its AstraZeneca (AZN) stake by 2.9% in Q2 2026, selling an estimated $221K and leaving 39,379 shares worth $7.47M. The position accounts for 0.61% of the portfolio, ranked #36.

Oxbow Advisors first reported a position in AZN in Q3 2024 and has held it in 8 quarters since. The position peaked at $8M in Q1 2026. 1,503 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Oxbow Advisors held 39,379 shares of AstraZeneca worth $7.47M as of Q2 2026.
Oxbow Advisors sold 1,173 AstraZeneca shares in Q2 2026, an estimated $221K.
AstraZeneca made up 0.61% of Oxbow Advisors's portfolio in Q2 2026, its #36 holding.
Oxbow Advisors first reported a position in AstraZeneca in Q3 2024 and has held it in 8 quarters since.
Oxbow Advisors's AstraZeneca position peaked at $8M in Q1 2026.
1,503 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Oxbow Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.